Vitrolife AB (publ)

Stockholm Stock Exchange:VITR.ST

Sector

🏥 Health Care

Industries

🩺 Medical Instruments

🧬 Biotechnology

🔬 Clinical Trials

💻 Telehealth

Location

Sweden

Market Cap

USD 2.01 B

Share Price

USD 14.82

Avg Daily Volume

193,487

Change (1 day)

2.00%

Change (1 year)

-8.60%

Change (YTD)

-23.69%

Vitrolife AB (publ) Revenue for the year ending December 31, 2024: USD 324.81 M

Vitrolife AB (publ) Revenue is USD 324.81 M for the year ending December 31, 2024, a -6.30% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Vitrolife AB (publ) Revenue for the year ending December 31, 2023 was USD 346.63 M, a 12.23% change year over year.
Vitrolife AB (publ) Revenue for the year ending December 31, 2022 was USD 308.85 M, a 66.89% change year over year.
Vitrolife AB (publ) Revenue for the year ending December 31, 2021 was USD 185.06 M, a 22.58% change year over year.
Vitrolife AB (publ) Revenue for the year ending December 31, 2020 was USD 150.96 M, a -4.14% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Revenue	Revenue	Gross Profit	Operating Income

Stockholm Stock Exchange: VITR.ST

Vitrolife AB (publ)

CEO	Ms. Bronwyn Brophy O´Connor
IPO Date	June 28, 2001
Location	Sweden
Headquarters	Gustaf Werners gata 2
Employees	1,150
Sector	🏥 Health Care
Industries Medical Instruments 🧬 Biotechnology 🔬 Clinical Trials 💻 Telehealth

Description

Vitrolife AB (publ), a medical device company, develops, produces, and markets products for assisted reproduction. It provides oocyte retrieval needles; sperm processing; in vitro fertilization media and oil; micromanipulation pipettes; labware; incubators; cryopreservation; and preimplantation genetic testing products. The company also offers EmbryoScope and Primo Vision time-lapse systems; time-lapse dishes; evaluation tools for time-lapse systems; and Octax laser and imaging systems, as well as log and guard systems and wireless sensors. It operates in Europe, the Middle East, and Africa; Asia; Japan and Pacific; and North and South America. The company was formerly known as Scandinavian IVF Science and changed its name to Vitrolife AB (publ) in 1998. Vitrolife AB (publ) was founded in 1994 and is headquartered in Gothenburg, Sweden.